Jon Dusting - 4Dmedical Chief Officer
| 4DX Stock | 0.46 0.01 2.22% |
Executive
Jon Dusting is Chief Officer of 4Dmedical
| Address | Melbourne Connect, Carlton, VIC, Australia, 3053 |
| Phone | 61 3 9545 5940 |
| Web | https://4dmedical.com |
4Dmedical Management Efficiency
The company has return on total asset (ROA) of (0.2695) % which means that it has lost $0.2695 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of (0.5054) %, meaning that it generated substantial loss on money invested by shareholders. 4Dmedical's management efficiency ratios could be used to measure how well 4Dmedical manages its routine affairs as well as how well it operates its assets and liabilities. At this time, 4Dmedical's Total Current Liabilities is comparatively stable compared to the past year. Liabilities And Stockholders Equity is likely to gain to about 126 M in 2024, whereas Non Current Liabilities Other is likely to drop slightly above 12.7 M in 2024.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| Yvonne Chong | Ampol | N/A | |
| Guy Brent | Woolworths | N/A | |
| Julian Longstaff | Commonwealth Bank | N/A | |
| Giles Hellyer | BHP Group Limited | N/A | |
| Khaidir Said | Aneka Tambang Tbk | 45 | |
| Paul Burnside | BHP Group Limited | N/A | |
| BCom BSc | Ampol | N/A | |
| BA LLB | Wesfarmers | N/A | |
| Isabelle Deschamps | Rio Tinto | 54 | |
| Archie Norman | Coles Group | 70 | |
| Bold Baatar | Rio Tinto | 50 | |
| Amanda McVay | Coles Group | N/A | |
| Sharbel ACA | Coles Group | N/A | |
| Rebecca Keenan | Wesfarmers | N/A | |
| James Martin | Rio Tinto | N/A | |
| Rob Telford | BHP Group Limited | N/A | |
| Sonia Scarselli | BHP Group Limited | N/A | |
| Rob McCartney | Woolworths | N/A | |
| Von Ingram | Woolworths | N/A | |
| Meaghan Davis | Ampol | N/A | |
| Anne Dekker | BHP Group Limited | N/A | |
Management Performance
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.27 |
4Dmedical Leadership Team
Elected by the shareholders, the 4Dmedical's board of directors comprises two types of representatives: 4Dmedical inside directors who are chosen from within the company, and outside directors, selected externally and held independent of 4Dmedical. The board's role is to monitor 4Dmedical's management team and ensure that shareholders' interests are well served. 4Dmedical's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, 4Dmedical's outside directors are responsible for providing unbiased perspectives on the board's policies.
| MBA BS, Senior Development | ||
| Jon Dusting, Chief Officer | ||
| Matt Tucker, Chief Officer | ||
| Jason Kirkness, Senior Affairs | ||
| Andreas MAICD, MD, Founder | ||
| Greg MD, Senior Director | ||
| Simon Glover, Chief Officer | ||
| Paul BA, Sr Devel | ||
| Beth Plunkett, Company Counsel | ||
| Naomi Lawrie, Company Counsel | ||
| Aidan BE, Senior Engineering | ||
| Michael Curtis, Chief Architect | ||
| Clint Rodgers, VP Communications | ||
| Rachael Tenkaten, Senior Product | ||
| BAppSci GradCertBus, Ex Director |
4Dmedical Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is 4Dmedical a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.51 | ||||
| Return On Asset | -0.27 | ||||
| Operating Margin | (7.55) % | ||||
| Current Valuation | 163.85 M | ||||
| Shares Outstanding | 411.6 M | ||||
| Shares Owned By Insiders | 21.96 % | ||||
| Shares Owned By Institutions | 5.64 % | ||||
| Price To Book | 2.67 X | ||||
| Price To Sales | 50.43 X | ||||
| Revenue | 3.75 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for 4Dmedical Stock Analysis
When running 4Dmedical's price analysis, check to measure 4Dmedical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy 4Dmedical is operating at the current time. Most of 4Dmedical's value examination focuses on studying past and present price action to predict the probability of 4Dmedical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move 4Dmedical's price. Additionally, you may evaluate how the addition of 4Dmedical to your portfolios can decrease your overall portfolio volatility.